Liposomal delivery system/adjuvant for tuberculosis vaccine

As reported by the World Health Organization, about 10 million individuals were infected with tuberculosis (TB) worldwide. Moreover, approximately 1.5 million people died of TB, of which 214,000 were infected with HIV simultaneously. Due to the high infection rate, the need for effective TB vaccinat...

Full description

Saved in:
Bibliographic Details
Published in:Immunity, Inflammation and Disease Inflammation and Disease, 2023-06, Vol.11 (6), p.e867-n/a
Main Authors: Moradi, Melika, Vahedi, Farzaneh, Abbassioun, Arian, Ramezanpour Shahi, Arash, Sholeh, Mohammad, Taheri‐Anganeh, Mortaza, Dargahi, Zahra, Ghanavati, Roya, Khatami, Seyyed Hossein, Movahedpour, Ahmad
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic
Antigens
Bacterial infections
Chemotherapy
Clinical trials
Drug resistance
HIV
Human immunodeficiency virus
Humans
Infections
Infectious diseases
Influenza
Mortality
Mycobacterium tuberculosis
Proteins
Review
subunit vaccine
Tuberculosis
Tuberculosis Vaccines
Tumor necrosis factor-TNF
Vaccination
Vaccines
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As reported by the World Health Organization, about 10 million individuals were infected with tuberculosis (TB) worldwide. Moreover, approximately 1.5 million people died of TB, of which 214,000 were infected with HIV simultaneously. Due to the high infection rate, the need for effective TB vaccination is highly felt. Until now, various methodologies have been proposed for the development of a protein subunit vaccine for TB. These vaccines have shown higher protection than other vaccines, particularly the Bacillus culture vaccine. The delivery system and safety regulator are common characteristics of effective adjuvants in TB vaccines and the clinical trial stage. The present study investigates the current state of TB adjuvant research focusing on the liposomal adjuvant system. Based on our findings, the liposomal system is a safe and efficient adjuvant from nanosize to microsize for vaccinations against TB, other intracellular infections, and malignancies. Clinical studies can provide valuable feedback for developing novel TB adjuvants, which ultimately enhance the impact of adjuvants on next‐generation TB vaccines. The delivery system and safety regulator are common characteristics of effective adjuvants in tuberculosis (TB) vaccines and the clinical trial stage. Based on our findings, the liposomal system is a superb adjuvant for vaccinations against TB, other intracellular infections, and malignancies.
ISSN:2050-4527
2050-4527
DOI:10.1002/iid3.867